Cytokinetics CYTK Investment Purchases
Investment Purchases at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's investment purchases.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's investment purchases?
- Cytokinetics (CYTK) reported investment purchases of $106.52M in Q1 2026.
- How has Cytokinetics's investment purchases changed year-over-year?
- Cytokinetics's investment purchases decreased by 33.1% year-over-year, from $159.11M to $106.52M.
- What is the long-term trend for Cytokinetics's investment purchases?
- Over 4 years (2021 to 2025), Cytokinetics's investment purchases has grown at a 19.3% compound annual growth rate (CAGR), from $525.04M to $1.06B.
- What does investment purchases mean?
- The total cash spent to buy investment securities.
- How do you interpret investment purchases?
- Higher outflows indicate active treasury management or the deployment of cash reserves into financial assets, while lower outflows may suggest a focus on liquidity preservation.
- How does investment purchases compare across companies?
- Common in biotech firms with large cash balances from equity raises; peers typically show significant fluctuations based on cash runway needs.